Recent Updates
Recently added Catalysts

QuidelOrtho Corporation

QDELFDA catalysts, PDUFA dates & pipeline intelligence
$8.92
▼ -0.65 · -6.79%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full QDEL financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $8.8852W HIGH $35.58
Volume
1.92 M
Value Traded
17.46 M
Short % Float
21.27%
Days to Cover
7.6
-16.01%Week
-37.23%1 Month
-39.93%3 Month
-28.01%6 Month
-90.2%5 Year
+131.41%All Time

Cash Data

Unlock QDEL cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
612.02 M
EPS (TTM)
-5.38
P/E Ratio
-
Ent. Value
870.02 M
Total Shares
68.58 M
Float Shares
68.00 M
Insiders
0.90%
Institutions
120.15%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Unlock every QDEL catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

QDEL Catalyst Timeline

Dated clinical, regulatory and corporate events for QuidelOrtho Corporation

Unlock the full QDEL catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How QDEL actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
No matching catalysts
Unlock all QDEL historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

No drug pipeline

QuidelOrtho Corporation is a diagnostics company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.

Clinical Trial Results

Readouts, endpoints and source filings for every QDEL program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
Scroll for more · summaries link to the source press release
Unlock every QDEL trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock QDEL insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Siegrist Jonathan PhilipOfficer (EVP of R&D & CTO)Option 18,657 32,076 held$0.00 10/15/2026
Unlock the full QDEL insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
SOLEUS CAPITAL MANAGEMENT, L.P. 0 % (-100 %) 210.80 K 20.00 K -73.33% ( -55.00 K)
Unlock every fund holding QDEL
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in QDEL
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see QDEL ownership
Insider and institutional ownership, quarter by quarter.

QDEL Short Interest

Shares sold short, counted twice a month.

21.27%
Short % of Float
of tradable shares sold short
14.5M
Shares Sold Short
+11.3% vs prior count
7.6 High
Days to Cover
trading days of normal volume to buy every short share back
1.9M
Avg Daily Volume
the average used for days to cover
Unlock QDEL short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
2026-11-20
Unlock QDEL option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live QDEL option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock QDEL options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How QDEL ranks across every disease it competes in

Competitive Position is a premium feature
See how QDEL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

QDEL News

QDEL
Nov 3, 2026
QDELGeneral

QuidelOrtho Reports Third Quarter 2026 Financial Results

QuidelOrtho reported a 12% decline in total revenue for Q3 2026, totaling $619 million. Despite challenges in China and a weaker respiratory season, the company noted a 2% revenue growth when excluding certain segments. A new cost transformation program is expected to yield over $80 million in annual savings starting in 2027.

Read more →
QDEL
Oct 29, 2026
QDELGeneral

Transforming Data Into Actionable Insights in the Lab

QuidelOrtho Corporation has released episode 62 of its Science Bytes podcast, focusing on AI and informatics in laboratory operations. The episode discusses the need for data integration to enhance clinical decision-making and addresses workforce challenges in clinical laboratories. Rodney Guzman, Vice President of Software Engineering, shares insights on transforming lab data into actionable clinical knowledge.

Read more →
QDEL
Oct 20, 2026
QDELConferences/Events
▲ +11.4%on this news

QuidelOrtho to Report Third Quarter 2026 Financial Results on November 3, 2026

QuidelOrtho Corporation will release its financial results for Q3 2026 on November 3, 2026, after market close. A conference call and webcast will follow to discuss these results. The event will be accessible via the company's Investor Relations page. QuidelOrtho focuses on advancing diagnostic solutions for improved patient outcomes.

Read more →
QDEL
Oct 15, 2026
QDELGeneral
▼ -7.2%on this news

QuidelOrtho Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

QuidelOrtho Corporation has announced the approval of equity awards under its 2026 Inducement Plan for two newly hired non-executive employees. The grants consist of restricted stock units (RSUs) totaling 50,323 shares, which will vest in equal annual installments over three years. This initiative aligns with Nasdaq Listing Rule 5635(c)(4) to attract new talent.

Read more →
QDEL
Oct 7, 2026
QDELGeneral

QuidelOrtho Appoints Sanjeev Sharma as Vice President of Investor Relations

QuidelOrtho Corporation has appointed Sanjeev Sharma as Vice President of Investor Relations, effective September 28, 2026. Sharma has over 20 years of experience in investor relations and corporate strategy, previously serving at Teva Pharmaceuticals. His expertise is expected to enhance communication with the investment community and support QuidelOrtho's strategic priorities.

Read more →
QDEL
Sep 24, 2026
QDELGeneral

Early Intervention Aids Emergency Medicine Teams in Identifying and Personalizing Sepsis Treatment

QuidelOrtho Corporation's latest podcast episode discusses strategies to lower sepsis rates in emergency medicine. Hosted by Josh Casey, the episode features Chris Sanchez, who shares insights on the importance of swift diagnosis and the use of serial procalcitonin testing. These strategies aim to improve treatment decisions and patient outcomes in critical care settings.

Read more →
QDEL
Aug 27, 2026
QDELConferences/Events

Faster Answers, Better Decisions: ADLM 2026 Highlights

QuidelOrtho Corporation's latest Science Bytes podcast episode highlights key insights from the 2026 ADLM Annual Conference. Experts discuss advancements in molecular diagnostics, including ultra-fast RT-PCR technology and the role of procalcitonin in antibiotic stewardship. The episode emphasizes the importance of rapid, actionable information for clinicians to improve patient outcomes.

Read more →
QDEL
Aug 6, 2026
QDELGeneral
▼ -24.7%on this news

QuidelOrtho Reports Second Quarter 2026 Financial Results

QuidelOrtho Corporation reported a 3% increase in total revenue for Q2 2026, driven by growth in Labs and Point of Care segments. However, the company experienced a GAAP net loss of $93 million and revised its full-year financial guidance downward due to challenges in the Chinese market and a softer global respiratory environment. Despite these setbacks, the company remains committed to improving cash conversion and strengthening its balance sheet.

Read more →
QDEL
Jul 24, 2026
QDELConferences/Events

QuidelOrtho to Report Second Quarter 2026 Financial Results

QuidelOrtho Corporation will announce its financial results for the second quarter of 2026 on August 6, 2026. Following the announcement, a conference call will take place to discuss the results. Interested parties can access the call through the company's Investor Relations webpage. QuidelOrtho continues to focus on advancing diagnostic solutions.

Read more →
QDEL
Jul 23, 2026
QDELGeneral

Beyond Fentanyl: How the Drug Crisis Is Changing

QuidelOrtho Corporation's latest podcast episode discusses the evolving drug overdose crisis, highlighting a decline in overdose deaths while addressing ongoing challenges. The episode features insights on counterfeit medications, polysubstance use, and emerging synthetic opioids. It emphasizes the importance of collaboration between laboratories and emergency departments to enhance toxicology testing and patient care.

Read more →
QDEL
Jul 15, 2026
QDELGeneral

QuidelOrtho Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

QuidelOrtho Corporation announced the approval of an Inducement Grant of 356,555 restricted stock units (RSUs) to Micah Young, the new Chief Financial Officer. This grant, approved by the Compensation Committee, is part of the 2026 Inducement Plan and aims to attract talent in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over three years, contingent on Mr. Young's continued employment.

Read more →
QDEL
Jun 23, 2026
QDELGeneral

QuidelOrtho Appoints Micah Young as Chief Financial Officer

QuidelOrtho Corporation has appointed Micah Young as Chief Financial Officer, effective July 6, 2026. Young succeeds Joseph M. Busky, who will assist in the transition. Young has extensive experience in medical technology finance and aims to enhance profitability and shareholder value at QuidelOrtho.

Read more →
QDEL
Jun 2, 2026
QDELGeneral

QuidelOrtho and Allo Hope Foundation Join Forces to Advance Education, Connection and Early Testing for Alloimmunized Pregnancies

QuidelOrtho and the Allo Hope Foundation have announced a collaboration to enhance prenatal care for women facing maternal red blood cell alloimmunization. This partnership aims to provide education, early testing, and improved connections between healthcare providers and patients. The initiative seeks to address gaps in care, particularly for underserved populations, and will produce educational materials for families and lab technicians.

Read more →
QDEL
May 21, 2026
QDELGeneral

When Blood Compatibility Becomes a Pregnancy Risk

QuidelOrtho Corporation has released a podcast episode discussing hemolytic disease of the fetus and newborn (HDFN), emphasizing the impact of maternal alloimmunization. The episode highlights the importance of awareness, timely diagnostics, and coordinated care to improve outcomes. Despite advancements, significant gaps in understanding and care persist, affecting patient management.

Read more →
QDEL
May 20, 2026
QDELConferences/Events

QuidelOrtho to Participate in Upcoming June 2026 Investor Conferences

QuidelOrtho Corporation announced its participation in two upcoming investor conferences in June 2026. The management team will present at the William Blair 46th Annual Growth Stock Conference and engage in a fireside chat at the Jefferies Global Healthcare Conference. Interested parties can access the events via the company's Investor Relations page.

Read more →
QDEL
May 6, 2026
QDELGeneral
▼ -6%on this news

QuidelOrtho Reports First Quarter 2026 Financial Results

QuidelOrtho Corporation reported its first-quarter financial results for 2026, highlighting a weaker respiratory season and disruptions in key markets. Despite these challenges, the company remains optimistic about its growth prospects, particularly following its acquisition of LEX Diagnostics and the launch of new products. The company has updated its financial guidance for the year, factoring in current market dynamics.

Read more →
QDEL
Apr 23, 2026
QDELGeneral
▼ -5.5%on this news

Understanding and Addressing Syphilis Trends - and What's Being Missed

QuidelOrtho Corporation's latest podcast episode discusses the concerning rise in congenital syphilis cases in the U.S., despite a decline in early-stage infections. Hosted by Josh Casey, the episode features insights from Andrea Ott-Vasconi on CDC data and emphasizes the need for improved diagnostic strategies and healthcare workflows. The discussion highlights missed screening opportunities and actionable steps to enhance prenatal care.

Read more →
QDEL
Apr 20, 2026
QDELGeneral

QuidelOrtho Corporation Completes Acquisition of LEX Diagnostics

QuidelOrtho Corporation has successfully acquired LEX Diagnostics for approximately $100 million, enhancing its molecular diagnostics capabilities. The LEX VELO System, which has received FDA clearance, offers rapid RT-PCR testing for Influenza A, Influenza B, and COVID-19. The company plans to launch this system commercially in the U.S. later this year, aiming to improve patient outcomes through faster diagnostics.

Read more →
QDEL
Apr 15, 2026
QDELGeneral

QuidelOrtho Announces Preliminary Revenue for the First Quarter 2026 and Provides Update on Full-Year 2026 Guidance

QuidelOrtho Corporation announced preliminary revenue of $615-$620 million for Q1 2026, affected by a weaker respiratory season and slower sales in China. The company anticipates negative free cash flow for the first half of 2026 but expects to achieve its full-year financial guidance. A conference call to discuss detailed results is scheduled for May 5, 2026.

Read more →
QDEL
Mar 24, 2026
QDELGeneral

Nathaniel Sisitsky Joins QuidelOrtho as Chief Legal Officer

QuidelOrtho Corporation has appointed Nathaniel Sisitsky as its new Chief Legal Officer, effective March 23, 2026. Sisitsky, who has over 25 years of experience in legal and governance roles, succeeds Michelle Hodges, who is retiring. He aims to support the company's mission of advancing diagnostics and improving patient care.

Read more →

About QuidelOrtho Corporation

San Diego, CA 6,500 employees quidelortho.com
Headquarters9975 SUMMERS RIDGE ROAD, SAN DIEGO, CA, 92121
BIOPHARMAWATCH ELITE
Trade the next QDEL catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime